A prospective cohort study of children with primary immunodeficiencies undergoing hematopoietic stem cell transplant in the United Kingdom investigated the extent and significance of Cryptosporidium carriage in this high risk group. Three of 42 children recruited were infected with Cryptosporidium, a lower proportion than previously described. One had serious disease. The underlying immunodeficiency likely had a bearing on the clinical presentation and possible outcome of infection.
C
ryptosporidium is a common protozoan parasitic cause of diarrhea in children worldwide. In those with profound T-cell immunodeficiency, including hematopoietic stem cell transplant (HSCT) recipients, it can cause protracted disease which may be fatal. 1, 2 Its role in sclerosing cholangitis in patients with dedicator of cytokinesis 8 deficiency has been highlighted. 3 Specific treatment options are limited, with no licensed treatment in the European Union; in the US, treatment with nitazoxanide is licensed for immunocompetent patients. There is no evidence for its efficacy in immunocompromised patients. 4 Some young children display asymptomatic Cryptosporidium carriage, 5, 6 which may precede symptomatic disease in vulnerable groups. 2 Detecting asymptomatic carriage and some symptomatic cases may require more sensitive methods than microscopy of stained smears, such as polymerase chain reaction (PCR), immunofluorescence microscopy, or immunomagnetic separation-immunofluorescence microscopy, 2, 6, 7 methods used by very few carriage studies.
This report describes a prospective cohort study of children with primary immunodeficiencies undergoing HSCT in the United Kingdom. The study objectives were to use highly sensitive methods to investigate the extent of carriage of Cryptosporidium and its clinical significance in this high risk group of patients.
METHODS
Over a 2.5-year period, all children <18 years old with primary immunodeficiencies undergoing HSCT at the pediatric bone marrow transplant units at the Royal Victoria Infirmary, Newcastle-upon-Tyne and Great Ormond Street Children's Hospital, London were eligible for inclusion in the study. Between them, these 2 centers perform the vast majority of bone marrow transplants in this patient group for the United Kingdom and Ireland.
Informed consent to participate in the study was obtained from patients and/or their guardians. Clinical patient data were supplied by the clinical team caring for the patients by means of a structured questionnaire. Possible risk factors for exposure were obtained from families, who completed a questionnaire that asked about the following risk factors: travel history, number of children living in same household, water supply at home (mains supply, private supply or group water scheme if in Ireland), whether drinking water had been boiled, swimming, pets, farm visits, nature and duration of childcare and school attendance. Stools from all study participants were collected before transplant and tested by routine microscopy (with modified Ziehl-Neelsen or Auramine phenol staining) in the local diagnostic laboratory and then in all cases by specialist tests at the national Cryptosporidium Reference Unit as follows: immunofluorescence microscopy (Crypto-Cel, Cellabs, Australia); PCR [small sub-unit (SSU) ribosomal RNA gene] 8 ; immunomagnetic separation-immunofluorescence microscopy (Isolate, TCS Biosciences, Buckingham, United Kingdom; Crypto-Cel, Cellabs). 7 In stools found to be Cryptosporidium positive, the species and subtype was confirmed by sequencing PCR products amplified from the SSU ribosomal RNA and gp60 genes. 8 Repeat samples were tested at 2 months posttransplant and again at 3 months after the end of immunosuppression (to give the patient a chance to clear carriage). Specimens were also tested on clinical grounds whenever a patient had symptoms consistent with cryptosporidiosis. Clinical and patient follow-up data were collected.
RESULTS
Forty-two patients undergoing bone marrow transplant for primary immune deficiency were recruited: 34 from the United Kingdom, 7 from the Republic of Ireland and 1 from Norway. The age range was 1 month to 17 years; median 2.5 years, mean 7.4 years (10 children were <1 year old, 8 children 1-2 years old, 8 children 2-5 years old and 16 children were 7-17 years old). The underlying diagnoses were severe combined immune deficiency (8 children), chronic granulomatous disease (7), CD40 ligand deficiency (5), hemophagocytic lymphohistiocytosis (3), dedicator of cytokinesis 8 deficiency (2), combined immunodeficiency syndrome (2), Omenn's syndrome (2), immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome (2), 1 with each of cartilage hair hypoplasia, X-linked lymphoproliferativelike syndrome, immunodeficiency, centromeric region instability, facial anomalies syndrome, Fas-associated death domain protein deficiency, osteopetrosis and Wiskott-Aldrich syndrome, 2 with complex autoimmune disease and 3 unclassified.
Three patients were found to be infected with Cryptosporidium. The presentation and clinical impact of the disease in these 3 cases were very different from one another. One patient (case 1) was infected with Cryptosporidium parvum (subtype IIaA19G4R1). This case was a 17-year-old male from Ireland who had first presented at the age of 5 years. The presentation and course of his undefined combined immunodeficiency resembled CD40 ligand deficiency, although this was excluded. At the age of 8 years, he had developed hepatosplenomegaly, diarrhea and cholangiohepatitis. At that time, his stools were consistently negative for Cryptosporidium by microscopy at his local microbiology laboratory. However, a liver biopsy revealed histologic evidence of Cryptosporidium and advanced liver disease.
Eventually, 3 years later, C. parvum (subtype IIaA19G4R1) was detected in a small bowel aspirate and subsequently was detectable intermittently in stool samples. He suffered severe disease attributable to the infection, leading to cholangitis and liver cirrhosis. At the age of 14 years, he underwent a liver transplant. Six weeks later, HSCT was performed. His first liver was rejected but a second transplant at age 15 was successful. He was treated with nitazoxanide and azithromycin throughout (unlicensed indications). His stools remained positive for Cryptosporidium a few months after his second liver transplant, and he continued on nitazoxanide for almost 2 years after that, in view of his immunosuppressant treatment, and concern about the new liver becoming infected. Long-term azithromycin was continued as part of his routine post-HSCT antibacterial prophylaxis. He had a number of risk factors for Cryptosporidium infection, most notably drinking nonboiled water from the household private water supply and living on a farm where he came into direct contact with cows and sheep.
Two cases had Cryptosporidium hominis but, surprisingly, did not appear to suffer clinical disease. One (case 2) was an 11-year-old girl from the United Kingdom and the other (case 3) a 7-year-old boy from Ireland, both with dedicator of cytokinesis 8 deficiency. In both, stool screening by microscopy pretransplant was negative. In case 2, stool screening was positive for C. hominis at 7 weeks post-HSCT when her CD4 count was 102 cells/mm 3 , but the patient was asymptomatic. She was nonetheless treated with azithromycin and nitazoxanide for 1 week (unlicensed indication). Treatment was then discontinued and the patient's CD4 counts rose to 586 cells/mm 3 within 2 more weeks. Her risk factors for C. hominis included contact with 3 younger siblings and infrequent use of swimming pools. She drank nonboiled tap water from a mains supply. Four weeks after the first positive sample, stool microscopy was negative, although still positive for Cryptosporidium by PCR. In case 3, routine screening locally by microscopy revealed presence of Cryptosporidium (identified as C. hominis) 4 weeks posttransplant when CD4 count was 387 cells/mm 3 . This boy was also asymptomatic. He was treated for 1 week with azithromycin (unlicensed indication). CD4 count reached 479 cells/mm 3 2 weeks later. Stool remained positive for Cryptosporidium by both microscopy and PCR for 8 weeks after infection but became negative after 10 and 15 weeks, respectively. He had been in the United Kingdom for 4 months, during which time he drank only boiled/filtered water. Risk factors for C. hominis included 1 younger sibling, using swimming pools (though not in the year before stool sampling), and attendance at day nursery and child minder for 2 years before starting school.
Typically, one would expect to find more severe disease in this vulnerable group, but the identification of these cases may indicate that asymptomatic carriage is more common than currently believed and is perhaps underdetected. These 2 cases presented within 1 month of each other in the same transplant unit. However, different gp60 subtypes were identified: IbA10G2 and IfA13G1, a finding which did not support the occurrence of transmission between these 2 patients within the unit. Increased observation and testing of the 9 patients on the unit at that time detected no further Cryptosporidium cases either clinically or microbiologically by testing stools using sensitive methods.
DISCUSSION
Three of the cases (3/42; 7%) were found to be infected with Cryptosporidium, more than 5 times the proportion detected using the same techniques among healthy children in a UK study of young children attending day-care settings. 6 All 3 cases occurred in children in the older age range (8, 11 and 7 years at first presentation). In developed countries, infants and children aged less than 2 years may be less likely to have been exposed to Cryptosporidium, particularly if they have presented with immune deficiency at a very young age and provided with precautionary advice. If cases aged <2 years are excluded from the analysis, 3/24 (12.5%) were infected.
In a previous study by McLauchlin et al, 2 12 of 25 (48%) children with primary immunodeficiencies tested prospectively were reported positive by PCR (but not microscopy) for Cryptosporidium-a much higher proportion than found in our study. They were of a relatively older age group than our series, but nonetheless the proportion infected was about 4 times that in our cohort even after excluding the under-twos. McLauchlin et al's cases were studied 10-15 years before our study when UK drinking water supply quality was not as good, and there was lower awareness of the risk of Cryptosporidium to this patient group. Since that time, the Water Supply (Water Quality) Regulations of 2000 were introduced, and an associated decline in cryptosporidiosis has been demonstrated. 9 Additionally, these high risk patients have been managed with strict advice on avoiding Cryptosporidium. 10 In McLauchlin et al's cohort, the children became sicker during transplant as a result of cryptosporidiosis. This might at least partly be explained by changes in the intensity of chemotherapy conditioning. However, the underlying diagnosis may also be relevant. In McLauchlin et al's study, nearly half (46%) had CD40 ligand deficiency; in our study, it was only 5/42 (12%). Of our 3 cases, the case resembling CD40 ligand deficiency was most severely affected. The worst affected child also had C. parvum infection, while the other 2 were infected with C. hominis, although the numbers in this study are too small to draw any conclusion regarding prognosis by infecting species of Cryptosporidium.
While overall only 1 in 34 study patients from the United Kingdom was infected with Cryptosporidium, 2/7 of those from Ireland were affected. The numbers in this study are small; however, a study including more patients would be lengthy because given the rarity of these conditions our patients took 2 years to recruit. Regulations supporting the European Drinking Water Directive and water safety plan approach are now being implemented in both countries.
